- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00548522
Pancreatic Islet Mass in Pregnancy in Type 1 Diabetes
Pancreatic Islet Mass in Pregnancy - Pilot Study
Visão geral do estudo
Status
Condições
Descrição detalhada
For the pilot phase of this study we will contact women with type 1 diabetes. The study will be explained and the subjects will be asked to sign an informed consent. Each subject will be asked to complete a brief medical history and lifestyle questionnaire.
Subjects will have blood samples taken for glucose and C-peptide and an intravenous arginine stimulation test. For the study tests, subjects will be asked to come to the Clinical Investigations Unit at the University of Alberta Hospital after an overnight fast only once during the study. The intravenous arginine test is a 10 minute test and does not cause hyperglycemia, an advantage over glucose in the setting of pregnancy.
Arginine infusion The intravenous arginine infusion test will be performed after an overnight fast greater than or equal to 8 hours. Subjects may drink water. For the Type 1 diabetic patients on insulin, long-acting insulin may be taken no less than 8 hours prior to the test; no food or short-acting insulin may be taken within 5 hours of the test. Lispro insulin should not be taken within 4 hours of the test.
On the morning of the test, an intravenous catheter, using a 20 gauge IV intercath, will be placed in an antecubital vein in one arm both for sampling and for infusion. Veins will be kept patent with an infusion of NaCl (0.9%) at 25 mL/hr throughout the test. The arm from which samples are obtained will be warmed to 55 C with a heating blanket to assist in the arterialization of the venous samples.
Baseline blood samples for glucose and C-peptide measurements will be drawn in a serum gel barrier tube at minus 10 and 0 minutes. An injection of 5 g of arginine (20 ml Sabex) diluted with 20 ml normal saline to equal 40 ml will be administered over 30 seconds, starting at time 0. The vein will immediately be flushed with 20mL normal saline. Blood samples for insulin and C-peptide will be drawn in barrier tubes at 2, 3, 4, 5, 7 and 10 minutes and serum will be separated and transferred into a cryogenic tube for analysis.
The acute C-peptide response to arginine is defined as the mean of the three highest insulin or C-peptide values between 2 and 5 minutes after the start of the arginine infusion with the mean of the minus 10 and 0 values subtracted.
Blood samples (basal and stimulated) will be analyzed for glucose and C-peptide. The insulin response will not be measured in these Type 1 subjects as it would be meaningless and the C-peptide response will be used.
Blood glucose will be determined by the hexokinase method using the Hitachi 917 system (Roche Diagnostics, Indianapolis, IN).
C-peptide assay An Ultrasensitive C-peptide ELISA method will be used to analyze for C-peptide. This test is specific for low concentrations of C-peptide in blood, specifically for patients with abnormal insulin secretion.
Statistical Analysis/Power calculation
Upon the significance test results for group differences, we will proceed with multiple comparisons of groups to locate the source of significance, while adjusting for multiple significance testing, using the method of Bonferroni.
Expected Possible Findings/ Conclusion
We hope to show that pancreatic islet mass may be present in women with Type 1 diabetes. Any demonstration of beta-cell recovery even in the unique setting of pregnancy would be exciting, as it would demonstrate progenitor beta cells present in the pancreas in type 1 diabetes subjects.
Tipo de estudo
Inscrição (Real)
Contactos e Locais
Locais de estudo
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 2B7
- University of Alberta Hospital
-
Edmonton, Alberta, Canadá, T6G 2S2
- University of Alberta
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Signed informed consent
- Females with Type 1 diabetes for at least 5 years
- Diabetes onset < 21 years
- Lean at diabetes onset
- Insulin required from diagnosis
- Willing to undergo intravenous arginine tolerance tests
Exclusion Criteria:
- Inability to provide informed consent
- Any medical condition that would preclude safe conduct of the intravenous arginine
- A family history which includes three generations of family members with the diagnosis of diabetes mellitus
- Women with elevated serum creatinine as arginine is excreted by the kidneys.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
---|
1
Pregnant (12 - 16 wks gestation) women with Type 1 diabetes
|
2
Pregnant women (34-38 wks gestation) with Type 1 diabetes
|
3
Post partum women with Type 1 diabetes
|
4
Non pregnant women with Type 1 diabetes
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
The documentation of Cpeptide in women with type 1 diabetes who are pregnant
Prazo: 1 year
|
1 year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Edmond A Ryan, MD, University of Alberta
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- UAHREB4503
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Diabetes tipo 1
-
Oxford Brookes UniversityUniversity of OxfordConcluídoAtividade física | Saúde Mental Bem-estar 1 | Função Cognitiva 1, Social | Academic Attainment | Fitness TestingReino Unido
-
SanionaConcluído
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionConcluído
-
Calliditas Therapeutics ABConcluído
-
National Cancer Institute, NaplesRecrutamentoCâncer de Ovário Recorrente Sensível à Platina BRCA Wild TypeItália
-
Merck Sharp & Dohme LLCRecrutamentoCâncer de Pulmão de Células Não Pequenas | Tumores Sólidos | Morte Celular Programada-1 (PD1, PD-1) | Ligante 1 de morte celular programada 1 (PDL1, PD-L1) | Ligante 2 de morte celular programada 1 (PDL2, PD-L2)Japão
-
Rambam Health Care CampusIsrael Science FoundationConcluído
-
Alvotech Swiss AGConcluído
-
PfizerConcluído
-
JKT Biopharma Co., Ltd.Recrutamento